Medical Xpress

MARCH 15, 2023

There's good news for those with multiple sclerosis (MS). A new study has found that female participants were no more likely to have a flare-up of the disease after receiving fertility treatments than they were before their treatments. Earlier studies had shown conflicting results.

89

89

Drug Discovery World

JANUARY 5, 2024

News round-up for 1-5 January by DDW Digital Content Editor Diana Spencer. The start of 2024 has seen quite a bit of regulatory activity, with the UK MHRA’s launch of a new procedure for assessing drugs, along with significant regulatory approvals for therapeutics for cytomegalovirus, melanoma, amyloidosis and multiple sclerosis.

Drugs 52

Drugs Medicine Regulation Production 52

Drug Discovery World

FEBRUARY 16, 2024

News round-up for 12-16 February by DDW Digital Content Editor Diana Spencer. This week our news highlights focus on skin conditions, with positive updates on hidradenitis suppurativa, systemic sclerosis, wound-healing, and other dermatological conditions like atopic dermatitis and vitiligo.

Dermatology 52

Dermatology Drugs Gene Expression Antibody 52

Pharmaceutical Technology

JANUARY 27, 2023

The FDA’s recent approval of TG Therapeutics’s Briumvi (ublituximab) against relapsing forms of multiple sclerosis (MS) is welcome news for the company after suffering a major setback in 2022 when the FDA extended its review of Briumvi by three months. Some 48% of patients on Briumvi also suffered with infusion reactions.

Marketing 130

Marketing Antibody Clinical Trials Clinical Trials 130

Drug Discovery World

MARCH 1, 2024

News round-up for 26 Feb – 1 March by DDW Digital Content Editor Diana Spencer. The news highlights this week all focus on regulatory decisions, both positive and negative.

Drugs 52

Drugs Allergies FDA Approval Medicine 52

Drug Discovery World

DECEMBER 1, 2023

News round-up for 27 November – 1 December by DDW Digital Content Editor Diana Spencer. The top stories: Potential disease-modifying therapy for Parkinson’s disease An experimental drug has shown potential as a disease-modifying therapy for Parkinson’s disease, according to a new study published in Nature Communications.

Gene Editing 52

Gene Editing Drugs Scientist Gene 52

The Pharma Data

JANUARY 13, 2021

Pregnancy Outcomes Examined for Women With Multiple Sclerosis. 13, 2021 — Women with pregnancy after versus before a multiple sclerosis (MS) diagnosis have fewer children and at an older age, according to a study published in the Feb. 1 issue of Multiple Sclerosis and Related Disorders. Professional.

Doctors 52

Doctors Doctor Development Research 52

The Pharma Data

NOVEMBER 2, 2020

2, 2020 — More than 50 percent of adults with multiple sclerosis (MS) report some form of caregiver abuse, according to a study published in the November issue of Multiple Sclerosis and Related Disorders. Many reported experiencing multiple forms of mistreatment. More News Resources. Professional.

Medicine 52

Medicine Research 52

The Pharma Data

JANUARY 21, 2021

Stem Cell Transplant May Slow Disability in Multiple Sclerosis. 21, 2021 — For patients with multiple sclerosis (MS), autologous hematopoietic stem cell transplantation (aHSCT) may prevent worsening of disability, according to a study published online Jan. More News Resources. Professional. THURSDAY, Jan.

Research 52

Research 52

Pharmaceutical Technology

JANUARY 30, 2023

The FDA approved fewer innovative drugs, New Molecular Entities (NMEs), in 2022 than it did in 2021: only 42 drugs compared to 59 drugs. Both are oncology treatments; Carvykti was authorised as a treatment for refractory multiple myeloma, and Opdualag was authorised as a treatment for metastatic melanoma.

Drugs 130

Drugs Manufacturing Contract Manufacturing FDA Approval 130

pharmaphorum

OCTOBER 8, 2021

NICE has delivered its first verdict on NHS funding of Janssen’s oral multiple sclerosis drug Ponvory, and it’s not good news for patients with the disease waiting for new treatment options.

Drugs 52

Drugs Medicine Manufacturing Production 52

pharmaphorum

APRIL 22, 2021

The cannabis-derived drug has been cleared by the EMA to treat seizures associated with tuberous sclerosis complex (TSC), a condition in which mostly benign tumours grow in vital organs of the body, including the brain. billion takeover by Jazz Pharma. .

FDA Approval 62

FDA Approval Marketing Drugs Sales 62

Drug Discovery World

NOVEMBER 29, 2023

The simulator could also be used by pharmaceutical companies to rapidly test multiple drug therapies and patient scenarios, increasing the speed and cost of drug development. In the future, the model could also be applied to study other inflammatory diseases such as lupus, multiple sclerosis, and chronic pancreatitis.

Development 52

Development Drugs Radiology Drug Trials 52

The Pharma Data

SEPTEMBER 11, 2020

In broader pharmaceutical news, Takeda has revealed it has agreed to divest its non-core portfolio of prescription therapies to Cheplapharm in exchange for an upfront payment of $562 million, while Mylan has announced an agreement to acquire the intellectual property and commercialisation rights to Aspen’s thrombosis business for €641.9

Vaccination 52

Vaccination Vaccine FDA Approval Clinical Trials 52

The Pharma Data

DECEMBER 30, 2020

Consumer News. Towards the end of March, the FDA approved two new treatments for multiple sclerosis (MS): Mayzent (siponimod) and Mavenclad (cladribine). It is very hard to justify what people with MS have to pay for their medications, even taking into account the cost of bringing a new drug to market.

FDA Approval 52

FDA Approval Drugs Marketing 52

The Pharma Data

DECEMBER 23, 2020

Very little of the difference was due to Parkinson disease and multiple sclerosis, both of which had a high proportion of neurologist involvement (>80 percent) even in the lowest quintile region. More News Resources. Professional. Distribution of Neurologists Across U.S. Varies Widely. WEDNESDAY, Dec. 23 in Neurology.

Research 52

Research 52

The Pharma Data

FEBRUARY 1, 2021

Food and Drug Administration (FDA) has approved a new intramuscular (IM) injection route of administration for Plegridy ® ( peginterferon beta-1a ) for the treatment of relapsing forms of multiple sclerosis (MS). References: 1 National Multiple Sclerosis Society. It is available in more than 60 countries.

FDA Approval 40

FDA Approval Bioequivalency Clinical Trials Clinical Trials 40

Drug Channels

JUNE 21, 2022

Conference highlights include: 40+ unique educational sessions organized into four dynamic tracks to help you focus on what is most important to you Continuing education credits for pharmacists, nurses, and technicians THREE KEYNOTE PRESENTATIONS Montel Williams, an Emmy Award winner, decorated former naval officer, inspirational speaker, author, entrepreneur, (..)

Pharmacy 82

Pharmacy Nurses Drugs 82

pharmaphorum

SEPTEMBER 14, 2020

The company has also denied press reports suggesting the patient developed transverse myelitis, an inflammation of the spinal cord that can be associated with viral infections as well as neurological conditions like multiple sclerosis. Good news for everyone the Oxford vaccine trials are back up and running.

Vaccination 75

Vaccination Vaccine Trials Protein 75

The Pharma Data

MAY 17, 2023

Roche’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase II FENopta study evaluating investigational oral fenebrutinib in adults with relapsing forms of multiple sclerosis (RMS).

FDA Approval 40

FDA Approval In-Vitro Trials Clinical Trials 40

The Pharma Data

NOVEMBER 13, 2020

“We know how to prevent measles outbreaks and deaths,” Dr Tedros Adhanom Ghebreyesus, WHO Director-General, said in a CDC news release. A multiple sclerosis drug may reduce COVID-19 patients’ risk of severe illness, researchers report.

Vaccination 52

Vaccination Vaccine Drugs Research 52

pharmaphorum

FEBRUARY 3, 2022

There’s a dearth of new product launches coming up however, and the company is expecting US revenues to continue declining this year which analysts have suggested could make a sale more difficult, as could untangling Sandoz from Novartis’ broader manufacturing operations.

Sales 92

Sales Gene Therapy Production Gene 92

The Pharma Data

NOVEMBER 25, 2020

25, 2020 — How does having multiple sclerosis (MS) affect a person’s odds for cancer ? The answer may depend on the type of cancer, new research shows. But there was good news, too: Their risk of breast and colon cancer is no higher than for people who don’t have MS, according to the Canadian researchers.

Research 52

Research Doctors Doctor Development 52

pharmaphorum

JULY 26, 2022

Beleaguered Biogen has been handed some encouraging news from the FDA, after the regulator agreed to complete its review of amyotrophic lateral sclerosis (ALS) therapy tofersen within six months. The rarity of SOD1-ALS means however that tofersen is unlikely to make big sales, even if it has a high price.

Drugs 44

Drugs Sales Marketing Trials 44

The Pharma Data

AUGUST 28, 2020

The top 10 news stories this week are focused on coronavirus vaccines and treatments, as China is set to move ahead with human testing of a potential vaccine that has been created using insect cells, while AstraZeneca has started a clinical trial of its antibody treatment designed to prevent and also treat symptoms of coronavirus.

Gene Therapy 52

Gene Therapy FDA Approval Gene Clinical Trials 52

pharmaphorum

SEPTEMBER 30, 2022

Patient organisations have been celebrating the FDA approval yesterday of Amylyx’ amyotrophic lateral sclerosis (ALS) therapy Relyvrio, after not one but two advisory committee meetings that arrived at different conclusions about the drug. Bad news for Biohaven. pic.twitter.com/Kck0tp1nSJ.

Drugs 82

Drugs Doctors Doctor FDA Approval 82

pharmaphorum

OCTOBER 18, 2021

Already struggling to make headway with its recently launched Alzheimer’s drug, Biogen suffered a major late-stage pipeline setback after its tofersen drug for amyotrophic lateral sclerosis (ALS) missed the mark in a late-stage study. 1/2) [link]. — MND Association (@mndassoc) October 17, 2021.

Trials 44

Trials Gene Editing Gene Gene Therapy 44

The Pharma Data

DECEMBER 16, 2020

16, 2020 — Researchers say a multiple sclerosis drug meant to slow physical disability also shows promise in improving mental acuity in people who are living with secondary progressive MS, an advanced form of the disease. WEDNESDAY, Dec.

Drugs 52

Drugs Research Marketing 52

The Pharma Data

DECEMBER 16, 2020

16, 2020 — Researchers say a multiple sclerosis drug meant to slow physical disability also shows promise in improving mental acuity in people who are living with secondary progressive MS, an advanced form of the disease. WEDNESDAY, Dec.

Research 52

Research Drugs Marketing 52

pharmaphorum

APRIL 25, 2022

The news came as Roche recorded a 10% increase in first-quarter revenues to CHF 16.4 billion), on strong US demand for rapid COVID-19 antigen tests, as well as the performances of multiple sclerosis therapy Ocrevus (ocrelizumab) and Hemlibra (emicizumab) for haemophilia. Diagnostics drive Q1 performance. billion ($17.2

Trials 67

Trials Hormones HR Sales 67

XTalks

JANUARY 7, 2022

We are only now starting to understand how metabolites produced by tumours can be used as biomarkers to accurately detect cancer,” Dr James Larkin, researcher on the University of Oxford study said in a news release from the university. “We

Research 98

Research Development 98

pharmaphorum

SEPTEMBER 28, 2021

Biohaven’s key pipeline drug verdiperstat has failed to have any Therapeutic effect in patients with the rare neurological disorder multiple system atrophy (MSA) – its lead indication – but the biopharma company isn’t ready to abandon the drug yet.

Trials 57

Trials Drugs Clinical Trials Clinical Trials 57

pharmaphorum

MAY 3, 2022

The headline news in the company’s first-quarter results statement (PDF) was Vounatsos’ departure, although he will remain at the helm of Biogen until a new CEO is found to help oversee a revitalisation of the company. First-quarter revenues fell 6% to just over $2.5

Sales 52

Sales FDA Approval Trials Clinical Trials 52

pharmaphorum

OCTOBER 13, 2020

The Geneva-based company has been operating under the radar since being formed to develop CRD1, a new oral formulation of the long-established drug chemotherapy cladribine which has been used intravenously as a treatment for leukaemia for years. — Arthur Roach (@DrArthurRoach) October 13, 2020.

Drugs 52

Drugs Antibody Development 52

Drug Channels

JUNE 7, 2021

Monica Pearson, distinguished journalist and humanitarian, and the first woman and first minority to anchor the daily evening news in Atlanta, Georgia. Montel Williams, an Emmy Award winner, decorated former naval officer, inspirational speaker, author, entrepreneur, multiple sclerosis patient, and advocate for patients worldwide.

Pharmacy 52

Pharmacy Drugs 52

The Pharma Data

DECEMBER 17, 2020

We at the LRA are thrilled to share this news about belimumab and look forward to future approvals of other lupus nephritis treatment options.”. Ocrelizumab is a humanized monoclonal antibody designed to target CD20-positive B cells, an immune cell thought to be a key cause of the myelin and axonal damage found in multiple sclerosis.

FDA Approval 52

FDA Approval Genome Genomics Production 52

Intouch Solutions

DECEMBER 20, 2022

An electric body suit helps people with multiple sclerosis, cerebral palsy, walk (Interesting Engineering) The Exopulse Mollii suit sends mild electrical stimulation to muscles, helping people with spastic muscles to walk and experience less pain. Should iomega ZIP get into telehealth cloud storage?

Branding 52

Branding Marketing Engineer Production 52